Fereshteh Ghiasvand

Fereshteh Ghiasvand

Auto-generated profile, based on publicly available information

Fereshteh Ghiasvand

Tehran University of Medical Sciences

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
SJSaeidreza JamaliMoghadamSiahkali
Saeidreza JamaliMoghadamSiahkali
BZBesharat Zarezade
Besharat Zarezade
SKSogol Koolaji
Sogol Koolaji
SSSeyedAhmad SeyedAlinaghi
SeyedAhmad SeyedAlinaghi
AZAbolfazl Zendehdel
Abolfazl Zendehdel
FGFereshteh Ghiasvand
Fereshteh Ghiasvand
Background: Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. Methods: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. Results: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. Conclusions: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020

1 October 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
ESEhsan Sekhavati
Ehsan Sekhavati
FJFatemeh Jafari
Fatemeh Jafari
SSSeyedAhmad SeyedAlinaghi
SeyedAhmad SeyedAlinaghi
SJSaeidreza Jamalimoghadamsiahkali
Saeidreza Jamalimoghadamsiahkali
SSSara Sadr
Sara Sadr
FGFereshteh Ghiasvand
Fereshteh Ghiasvand

27 November 2021 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
NTNegar Toroghi
Negar Toroghi
LALadan Abbasian
Ladan Abbasian
ANAnahid Nourian
Anahid Nourian
EDEffat Davoudi-Monfared
Effat Davoudi-Monfared
HKHossein Khalili
Hossein Khalili
MYMir Saeed Yekaninejad
Mir Saeed Yekaninejad

28 August 2020 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
HRHamid Rahmani
Hamid Rahmani
EDEffat Davoudi-Monfared
Effat Davoudi-Monfared
ANAnahid Nourian
Anahid Nourian
MNMorteza Nabiee
Morteza Nabiee
SSSetayesh Sadeghi
Setayesh Sadeghi
MYMir Saeed Yekaninejad
Mir Saeed Yekaninejad
Background The role of the antiviral therapy in treatment of COVID-19 is still a matter to be investigated. Also efficacy and safety of antiviral regimens were not compared according severity of the disease. In this study the efficacy and safety of hydroxychloroquine plus atazanavir/ritonavir was compared in patients with moderate and severe COVID-19. Methods We prospectively evaluated the clinical outcomes of 213 patients with COVID-19 during the hospitalization course and up to 56 days after the hospital discharge. The disease was categorized to moderate and severe based on the severity of pneumonia and peripheral oxygen saturation (SpO2). The patients received the national treatment protocol containing hydroxychloroquine (400 mg BD in first day and then 200 mg BD) plus atazanavir/ritonavir (300/100 mg daily) for 7 days. Main outcomes included discharge rates at day 7, 14 and 28, 28-day mortality, rate of intensive care unit (ICU) admission and intubation, length of hospital and ICU stay and incidence of adverse events. Results The mean (SD) age of patients was 60(14) years and 53% were male. According to WHO definition, 51.64% and 48.36% of the patients had moderate (SpO2 ≥ 90%) and severe disease (SpO2 < 90%) at baseline, respectively. The discharge rate of the moderate group was significantly higher than the severe group at day 7, 14 and 28 (HR = 0.49; 95% CI: 0.35–0.69, p = < 0.001 at day 7, HR = 0.48; 95% CI: 0.35–0.66, p = < 0.001 at day 14 and HR = 0.49; 95% CI: 0.36–0.67, p = < 0.001at day 28). The 28-day mortality of the severe group was six times higher than the moderate group (HR = 6.00; 95% CI: 2.50–14.44), p = < 0.001). The need of admission in ICU for the severe group and the moderate group was 37.86% and 18.18% of the patients. Length of hospital stay was significantly shorter in the moderate group in comparison with the severe group (5 ± 4 vs. 8 ± 6 days, p < 0.001). Patients in the moderate group experienced the serious adverse events and complications less than the severe group. The discharged patients were followed up to 56 days after discharge. Some of the patients complained of symptoms such as exertional dyspnea, weakness and new-onset hair loss. Conclusion Our study did not support the use of hydroxychloroquine plus atazanavir/ritonavir in patients who had SpO2 < 90% at the time of hospital admission. SpO2 was the only predictor of clinical outcomes (duration of hospital stay, discharge from the hospital and mortality) in patients treated with hydroxychloroquine plus atazanavir/ritonavir. Graphical abstract

3 February 2022 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MSMohammadreza Salehi
Mohammadreza Salehi
MMMahdi Barkhori Mehni
Mahdi Barkhori Mehni
MAMohammadmehdi Akbarian
Mohammadmehdi Akbarian
SGSamrand Fattah Ghazi
Samrand Fattah Ghazi
NRNasim Khajavi Rad
Nasim Khajavi Rad
FGFereshteh Ghiasvand
Fereshteh Ghiasvand
Background: During the COVID-19 pandemic, different treatments have been used in critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in various studies as an effective option. Our study aims to access the efficacy of IVIG in critically ill COVID-19 patients. Methods: In this retrospective matched cohort study, records of three tertiary centers with a large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using an independent t test and one-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate. Results: The duration of hospitalization in the IVIG group was significantly longer than standard treatment (13.74 days vs. 11.10 days, p < 0.05). There was no significant difference between the two groups in ICU length of stay, the number of intubated patients, and duration of mechanical ventilation (p > 0.05). Also, initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (p < 0.01). Conclusion: Our data indicate that the use of IVIG in critically ill COVID-19 patients could not be beneficial, based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation, and even mortality rate.

14 April 2021 in Iranian Journal of Microbiology
Verified
Journal Article
Open access
ZAZahra Ahmadinejad
Zahra Ahmadinejad
MMMaryam Mokhtaryan
Maryam Mokhtaryan
ASArezoo Salami
Arezoo Salami
MTMonavar Talebian
Monavar Talebian
HIHamideh Irajian
Hamideh Irajian
FGFereshteh Ghiasvand
Fereshteh Ghiasvand
Background and Objectives: Tuberculosis is one of the main reasons for mortality in liver transplant recipients. Since Iran is considered as a tuberculosis-endemic country, the present study aims to evaluate the outcome of latent tuberculosis infection in transplant recipients after liver transplantation. Materials and Methods: The present analytical cross-sectional study was performed on transplanted patients in Imam Khomeini Complex Hospital in Tehran Iran from 2006 to 2016. All patients with positive tuberculin skin test were enrolled. Variables including demographic information, therapeutic and outcome data were gathered and analyzed. Results: Among 675 transplant recipients, 100 patients had positive tuberculin skin test (14.8%). Sixty seven percent of recipients were men and the mean age was 72.67 ± 1.3 years. All patients' received Isoniazid prophylaxis before transplantation. The mean duration of anti- tuberculosis prophylaxis before and after transplant were 2.7 ± 1.9 and 3.6 ± 5.5 months, respectively. Tuberculosis has not been occurred in none of these patients after a mean follow up time of 45.21 ± 3 months. During the study period, four subjects infected by Mycobacterium tuberculosis, while their skin test was negative before transplant. Conclusion: According to our study, tuberculin skin test is a reliable and sensitive test for diagnosis of latent tuberculosis in liver transplant candidates. Isoniazid prophylaxis is well tolerated in patients with end stage liver diseases and liver transplant recipients.